ArticleNPJ vaccines2018
Design and production of conjugate vaccines against
Article in NPJ vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Development and validation of immunological assays for preclinical evaluation of a novel bivalent typhoid conjugate vaccine.Human vaccines & immunotherapeutics · 2026Article
- Modular Development of aNanomaterials (Basel, Switzerland) · 2026Article
- Preclinical evaluation of a bivalent conjugate vaccine againstFrontiers in immunology · 2026Article
- Glycosylated Foot-And-Mouth Disease Virus-Like Particles Produced in Pichia Pastoris Enhance Stability and Immunogenicity.Microbial biotechnology · 2025Article
- Modular assembly and immunological evaluation of a promising bioconjugate nanovaccine against Klebsiella pneumoniae O2 serotype.NPJ vaccines · 2025Article
- Recent Advances in Bioconjugate Vaccine Development.Vaccines · 2025Review
- Genetic engineering of E. coli K-12 for heterologous carbohydrate antigen production.Microbial cell factories · 2025Article
- A Bioconjugate Vaccine Against Extra-Intestinal PathogenicVaccines · 2025Article
- Article
- Recent advances in the biosynthesis of polysaccharide-based antimicrobial glycoconjugate vaccines.Frontiers in microbiology · 2024Review
- Progress towards a glycoconjugate vaccine against Group A Streptococcus.NPJ vaccines · 2023Review
- Review
- A candidate glycoconjugate vaccine induces protective antibodies in the serum and intestinal secretions, antibody recall response and memory T cells and protects against both typhoidal and non-typhoidalFrontiers in immunology · 2023Article
- Article
- A bioconjugate vaccine againstFrontiers in bioengineering and biotechnology · 2023Article
- Article
- Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines.Microbial cell factories · 2022Article
- Construction of Orthogonal Modular Proteinaceous Nanovaccine Delivery Vectors Based on mSA-Biotin Binding.Nanomaterials (Basel, Switzerland) · 2022Article
- Safety and immunogenicity of a new glycoengineered vaccine against Acinetobacter baumannii in mice.Microbial biotechnology · 2022Article
- A Short Peptide of Autotransporter Ata Is a Promising Protective Antigen for Vaccination AgainstFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enteric fever, mainly caused by
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.